dr. S.J. Vastert
Associate Professor
- Laboratory for Translational Immunology (LTI)
- Immuno/reuma onderzoek 5
Contact
Biography
Bas is a pediatric rheumatologist in the “EULAR center of excellence in rheumatology" Wilhelmina Children’s Hospital Utrecht. Besides being an esteemed clinician in the field of Pediatric Rheumatology, he has developed into a translational researcher, with a PhD on mechanisms of disease and therapy in severe JIA in 2013. From 2015, he has been starting a translational research group together with Jorg van Loosdregt, molecular biologist. They currently supervise 5 PhD students, 1 post-doc and 2 technicians together, within the Center of Translational Immunology in Utrecht (v Loosdregt-Vastert group). Their labgroup aims to translate cutting edge science into clinical benefit for patients and their research focusses on systemic JIA and on development of novel treatment strategies for JIA. Bas is currently leading a multi-center prospective trial implementing a biomarker driven stop-strategy for rIL-1RA therapy in systemic JIA in the Netherlands (the ESTIS trial).
In addition, as a designated Young Investigator, Bas is the Dutch lead for all translational laboratory studies within UCAN CAN DU (major infrastructural research project 2017-2021 in Canada and the Netherlands).
Key words: Translational research in childhood arthritis, biology of systemic JIA, (regulation of) auto-inflammation, regulation of autoimmune inflammation, epigenetics.
Side Activities
- member editoreal board van Pediatric Rheumatology Online Journal
- associate editor Rheumatology
Fellowship and Awards
- 2007: Young investigator Meeting, Pediatric rheumatology European Society: Award for best basic abstract .
- 2014: Wilhelmina Research Fund (co-applicant), € 150 000 : Dissecting the complex role of S100-proteins in systemic juvenile idiopathic arthritis.
- 2015: ZonMW Rational Pharmacotherapy grant, € 340 000 : Biomarker guided treatment and stop strategy for rIL-1RA therapy in systemic JIA.
- 2016-2019: Wilhelmina Kinderziekenhuis Fonds, Rosenberg foundation / Vrienden WKZ (€340 000): Modulation of Treg in JIA by Nicotinamide. Principal Investigator, no overlap.
- 2016-2021: ZonMW grant, Rational Pharmacotherapy for implementation of biomarker guided tapering strategy of rIL-1RA in systemic JIA (€340 000 + €190 000 contribution Sobi). Principal Investigator, clinical trial, no overlap.
- 2017-2021: UCAN CAN DU: (8,0 mln Can$). Canada – Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic diseases. Young Investigator, NL lead for laboratory studies within UCAN CAN DU. (PI: R. Yeung, NM Wulffraat, co-PI JF Swart, S. Benseler).
Research Output (95)
Anakinra in children and adults with Still's disease
Vastert Sebastiaan J., Jamilloux Yvan, Quartier Pierre, Ohlman Sven, Osterling Koskinen Lisa, Kullenberg Torbjörn, Franck-Larsson Karin, Fautrel Bruno, De Benedetti Fabrizio 1 nov 2019, In: Rheumatology (United Kingdom). 58 , p. VI9-VI22
Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis
Gohar Faekah, Mcardle Angela, Jones Melissa, Callan Niamh, Hernandez Belinda, Kessel Christoph, Miranda-Garcia Maria, Lavric Miha, Holzinger Dirk, Pretzer Carolin, Lainka Elke, Vastert Sebastiaan J., De Roock Sytze, Fitzgerald Oliver, Pennington Stephen R., Foell Dirk 1 aug 2019, In: Annals of the Rheumatic Diseases. 78 , p. 1107-1113 7 p.
Consensus-based recommendations for the management of juvenile localised scleroderma
Zulian Francesco, Culpo Roberta, Sperotto Francesca, Anton Jordi, Avcin Tadej, Baildam Eileen M., Boros Christina, Chaitow Jeffrey, Constantin Tamàs, Kasapcopur Ozgur, Knupp Feitosa De Oliveira Sheila, Pilkington Clarissa A., Russo Ricardo, Toplak Natasa, Van Royen Annet, Saad Magalhães Claudia, Vastert Sebastiaan J., Wulffraat Nico M., Foeldvari Ivan 1 aug 2019, In: Annals of the Rheumatic Diseases. 78 , p. 1019-1024 6 p.
The European network for care of children with paediatric rheumatic diseases:Care across borders
Dolezalova Pavla, Anton Jordi, Avcin Tadej, Beresford Michael W., Brogan Paul A., Constantin Tamas, Egert Yona, Foeldvari Ivan, Foster Helen E., Hentgen Veronique, Kone-Paut Isabelle, Kuemmerle-Deschner Jasmine B., Lahdenne Pekka, Magnusson Bo, Martini Alberto, McCann Liza, Minden Kirsten, Ozen Seza, Schoemaker Casper, Quartier Pierre, Ravelli Angelo, Rumba-Rozenfelde Ingrida, Ruperto Nicola, Vastert Sebastian, Wouters Carine, Zulian Francesco, Wulffraat Nico M., Beresford Michael W., Huemer Christian, Joos Rik, Mihaylova Dimitrina, Harjacek Miroslav, Mina Elpida, Nielsen Susan, Foell Dirk, Vougiouka Olga, Orbán Ilona, Uziel Yosef, Ruperto Nicolino, Wulffraat Nico M., Flato Berit, Smolewska Elzbieta, Melo-Gomes Jose Antonio, Lazar Calin, Susic Gordana, Dallos Tomas, De Inocencio Jaime, Berntson Lillemor, Hofer Michael, Boyko Yaryna 1 jul 2019, In: Rheumatology (United Kingdom). 58 , p. 1188-1195 8 p.
Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis:A scoping review
Kip Michelle M.A., Currie Gillian, Marshall Deborah A., Grazziotin Lago Luiza, Twilt Marinka, Vastert Sebastiaan J., Swart Joost F., Wulffraat Nico, Yeung Rae S.M., Benseler Susanne M., Ijzerman Maarten J., Bonsel Gouke, Feldman Brian M., Hoppenreijs Esther, Lang Bianca, Leblanc Claire, Sepulveda Ana, Toupin-April Karine, Van Pelt Philomine, Van Royen-Kerkhof Annet 6 mei 2019, In: Pediatric Rheumatology. 17 13 p.
European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative
Ozen Seza, Marks Stephen D, Brogan Paul, Groot Noortje, de Graeff Nienke, Avcin Tadej, Bader-Meunier Brigitte, Dolezalova Pavla, Feldman Brian M, Kone-Paut Isabelle, Lahdenne Pekka, McCann Liza, Pilkington Clarissa, Ravelli Angelo, van Royen Annet, Uziel Yosef, Vastert Bas, Wulffraat Nico, Kamphuis Sylvia, Beresford Michael W 16 mrt 2019, In: Rheumatology (Oxford, England). 58 , p. 1607-1616 10 p.
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis:Results From a Five-Year Follow-Up Study
ter Haar Nienke M., van Dijkhuizen E. H.Pieter, Swart Joost F., van Royen-Kerkhof Annet, el Idrissi Ayman, Leek Arjen P., de Jager Wilco, de Groot Mark C.H., Haitjema Saskia, Holzinger Dirk, Foell Dirk, van Loosdregt Jorg, Wulffraat Nico M., de Roock Sytze, Vastert Sebastiaan J. 8 mrt 2019, In: Arthritis & Rheumatology. 71 , p. 1163-1173 11 p.
Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy:Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression
Korte-Bouws Gerdien A.H., Albers Eline, Voskamp Marije, Hendriksen Hendrikus, de Leeuw Lidewij R., Güntürkün Onur, de Roock Sytze, Vastert Sebastiaan J., Korte S. Mechiel 1 mrt 2019, In: Pharmaceuticals. 12
Tocilizumab as an effective treatment in children with refractory intermediate and panuveitis
Wennink R. A. W., Ayuso V. Kalinina, de Vries L., Vastert S. J., de Boer J. H. mrt 2019, In: Acta Ophthalmologica. 97 , p. 16-16
Restoring T cell tolerance, exploring the potential of histone deacetylase inhibitors for the treatment of juvenile idiopathic arthritis
Nijhuis Lotte, Peeters Janneke G.C., Vastert Sebastiaan J., Van Loosdregt Jorg 7 feb 2019, In: Frontiers in Immunology. 10